Efficacy and Safety of Corticosteroids in COVID-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

86 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-02-14

Study Completion Date

2020-04-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There is still controversy about the effective of glucocorticoids for the treatment of novel coronavirus pneumonia. This is a prospective randomized controlled trails. The aim is to explore the effectiveness and safety of glucocorticoids in the treatment of novel coronavirus pneumonia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of the Efficacy of High Doses of Methylprednisolone in SARS-CoV2 ( COVID-19) Pneumonia Patients

NCT04673162

Covid19

COMPLETED PHASE3

Evaluation of Corticosteroids Use and Clinical Outcomes in Hospitalized COVID-19 Patients: A Retrospective Study

NCT05844410

COVID-19 Pandemic Morality

COMPLETED

Early Short Course Corticosteroids in COVID-19

NCT04374071

COVID Pneumonia, Viral

COMPLETED

The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia

NCT04263402

2019-nCoV Severe Pneumonia

UNKNOWN PHASE4

Corticosteroid Therapy for Severe Community-Acquired Pneumonia

NCT02552342

Community Acquired Pneumonia

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Novel Coronavirus Pneumonia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MP group

Group Type EXPERIMENTAL

Methylprednisolone

Intervention Type DRUG

Methylprednisolone 1mg/kg/day ivgtt for 7 days.

Con group

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Methylprednisolone

Methylprednisolone 1mg/kg/day ivgtt for 7 days.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age more than 18 years old
* accord with the clinical diagnosis and/ or etiological diagnosis diagnostic criteria of Novel coronavirus pneumonia (COVID-19).
* admitted in the general wards
* be able to sign informed consent

Exclusion Criteria

* severe immunosuppression (HIV infection, long-term use of immunosuppressive agents
* pregnant or lactation period women
* glucocorticoids are needed for other diseases
* unwilling or unable to participate or complete the study
* participate in other study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No